BioAdaptives Q3: $5,144 Cash, Going-Concern Doubt, 223.7M Shares After Debt Conversions
BDPT sits 50% above its 52-week low of $0.001.
Summary
BioAdaptives reported $5,144 of cash and a $1.50M Q3 net loss, with management flagging substantial doubt about going concern and shares outstanding up to 223.7M from 12.0M after debt conversions.
Key Events · Earnings and Guidance · BDPT
-
Cash Nearly Exhausted
Cash fell to $5,144 at September 30, 2026 from $158,445 at December 31, 2025, against $2,704,765 of current liabilities.
-
Going-Concern Doubt
Accumulated deficit reached $12,180,515, and management states substantial doubt about the company's ability to continue as a going concern, with no formal funding commitments in place.
-
Loss Driven by Non-Cash Mark
Q3 2026 net loss of $1,498,315 versus $379,502 a year earlier, including a $1,420,251 non-cash change in fair value of derivative liabilities; operating loss was $292,498.
-
Massive Debt-Conversion Dilution
Shares outstanding rose to 223,677,577 from 12,008,725 at December 31, 2025, with 206,668,852 shares issued for conversion of $79,000 principal and $69,878 accrued interest.
Analysis · BDPT · Life Sciences
Cash of just $5,144 at September 30, 2026 against $2.70M of current liabilities leaves management with substantial doubt about the company's ability to continue as a going concern. The quarter's $1.50M net loss was driven mostly by a $1.42M non-cash mark-to-market change in derivative liabilities rather than operations, but the cash position is the real problem: no formal commitments for new funding are in place, and the plan is to issue more stock for cash and services. Share count already exploded from 12.0M to 223.7M in nine months as noteholders converted debt at 65% of the lowest traded price. The filing also discloses a material weakness in internal controls and that the company is in default on its 2018 12% debentures. The October 29 Xycota acquisition announced in the November 4 8-K is noted as a subsequent event, but funding is tied to closing and milestones, so it does not solve the near-term cash shortfall.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDPT was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $268.4K. The 52-week trading range was $0.00 to $0.07. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.